Lantern Pharma Announces Closing of Public Offering of $69 Million USD and Full Exercise of Underwriter's Over-Allotment Option Jan 20 Written by Health Wildcatters Health Wildcatters Previous Previous Technology Is Rapidly Changing Cancer Care Next Next Despite Frustration Over Long COVID-19 Vaccination Lines, Doctor Says There's Hope on Horizon
Lantern Pharma Announces Closing of Public Offering of $69 Million USD and Full Exercise of Underwriter's Over-Allotment Option Jan 20 Written by Health Wildcatters Health Wildcatters